2359:HKG
WuXi AppTec Ord Shs H
HK$208.00
arrow_downward
-0.48%(-1.00) 1D
Oct 9, 4:08:06 PM GMT+8 · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2359...
Open
HK$210.80
High
HK$211.80
Low
HK$198.50
Mkt. cap
573.98B
Avg. vol.
3.98M
Volume
10.64M
Dividend
1.15%
Quarterly dividend
HK$0.60
Ex-dividend date
Sep 4, 2026
P/E ratio
25.47
52-wk high
HK$219.20
52-wk low
HK$96.70
EPS
HK$8.17
No. of employees
36K
Open
HK$210.80
High
HK$211.80
Low
HK$198.50
Mkt. cap
573.98B
Avg. vol.
3.98M
Volume
10.64M
Dividend
1.15%
Quarterly dividend
HK$0.60
Ex-dividend date
Sep 4, 2026
P/E ratio
25.47
52-wk high
HK$219.20
52-wk low
HK$96.70
EPS
HK$8.17
No. of employees
36K
News stories
From web sources and news partners
AD HOC NEWS
·
3 hours ago
Huaxi keeps Buy rating for WuXi AppTec stock
AD HOC NEWS
·
8 hours ago
WuXi AppTec stock loses 2.44 percent pre-market to EUR 23.23
AD HOC NEWS
·
18 hours ago
WuXi AppTec stock loses 5.33 percent after-hours to EUR 23.79
AD HOC NEWS
·
1 day ago
WuXi AppTec stock earns EcoVadis Gold for a third year
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe.
Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
About WuXi AppTec Ord Shs H
CEOSteve Yang | Ge Li
Employees35.6K
FoundedDec 1, 2000
Headquarters-
SectorHealth care
Websitewuxiapptec.com.cn